// App-Quantinova.ai

AB0697 (2022) : Dramatic reduction of mortality rate by tofacitinib in anti-MDA-5 antibody-positive patients with rapidly progressive interstitial lung disease

Researchers

Presenter

  • C. W. Tseng

Principal Investigators

  • M. Satoh

  • Y. M. Chen

Medical Centers

  • Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Republic of China

  • National Chung Hsing University, Department of Post-Baccalaureate Medicine, College of Medicine, Taichung, Taiwan, Republic of China

  • University of Occupational and Environmental Health, Department of Clinical Nursing, School of Health Sciences, Kitakyushu, Fukuoka, Japan

  • Taichung Veterans General Hospital, Department of Radiation Oncology, Taichung, Taiwan, Republic of China

  • National Chung Hsing University, Rong Hsing Research Center for Translational Medicine & Ph.D. Program in Translational Medicine, Taichung, Taiwan, Republic of China

  • National Yang Ming Chiao Tung University, School of Medicine, College of Medicine, Taipei, Taiwan, Republic of China

Locations

  • Republic of South Korea

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Interstitial lung disease

  • Pulmonary fibrosis

  • Dyspnea

Biomarkers

  • Lactate

  • Lactate dehydrogenase

  • White Blood Cell

Drug/Treatment

  • Mycophenolic acid

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Tasocitinib

  • Rituximab

  • IVIG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved